Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

From the rupee's continued slide, the Cabinet's approval of two reform bills, to Ozempic's launch in India, here are the key news events that shaped the week gone by.

Novo Nordisk launched Ozempic in India on Friday—and the weight-loss drug will sell at a massive discount there, compared ...

We recently published 13 Best ADR Stocks to Invest In. Novo Nordisk A/S (NYSE:NVO) is one of the best ADR stocks. Healthcare giant Novo Nordisk A/S (NYSE:NVO)’s shares were downgraded by Argus ...

A proposed new federal law could provide some competitive guardrails for the company's most important product.

Novo Nordisk (NVO) closed the most recent trading day at $50.29, moving +2.53% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.21%. Elsewhere, the Dow gained 1.35%, ...

A perfect storm of clinical setbacks, intensifying competition, and internal upheaval has triggered a historic sell-off in ...

The coming year, 2026, is shaping up as a critical operational and financial test. A head-to-head comparative study between Novo Nordisk's CagriSema and Eli Lilly's Zepbound, scheduled for 2026, will ...

The price/sales TTM, EV/Sales TTM, and EV/EBITDA TTM of Novo, as compared to its peers, repeat substantially the same story ...

Stay up-to-date with the Sun Pharma Stock Liveblog, your comprehensive source for real-time updates and detailed analysis on ...

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term losses from the stock lately, despite its ...

Global obesity-drug sales could exceed $130–150B by the mid-2030s, driven by GLP-1/GIP drugs and expanding access beyond the ...